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D-Galactopyranosyl residues were coupled to poly(L-lysine) and the antiviral agents arabinofuranosylade- 
nine S-monophosphate (ara-AMP) and acyclovir were conjugated with this glycosylated polymer. In mice 
the ara-AMP conjugate accomplished a selective drug delivery to liver cells. 
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1. INTRODUCTION 
Albumin after conjugation with D-galacto- 
pyranosyl residues binds to Ashwell’s receptor for 
galactosyl terminating glycoproteins [ 1,2] and 
specifically penetrates into liver cells [3]. Galac- 
tosylated albumin has been successfully used in 
mouse as a hepatotropic vector of 9-/3-D-arabino- 
furanosyladenine 5 ’ -monophosphate (ara-AMP) 
[4-61 and of 9-(2-hydroxyethoxymethyl)guanine 
(acyclovir) (Fiume et al., unpublished), two an- 
tiviral agents employed in the treatment of chronic 
hepatitis B (review [7]). The present experiments 
were undertaken to ascertain whether poly(L- 
lysine) after coupling to D-galactosyl residues can 
also accomplish a selective delivery of ara-AMP 
and acyclovir (ACV) to the hepatic cells. Poly(L- 
lysine) has been used by several different authors 
as a drug carrier in experimental cancer chemo- 
therapy (review [S]). 
2. MATERIALS AND METHODS 
2-Imino-2-methoxyethyl 1-thioglycoside of D- 
galactose was prepared and covalently attached to 
poly(L-lysine) (Mr 47 000) (Sigma) according to Lee 
et al. [9]. The resulting complex (Gal-poly(L- 
lysine)) had 320 ,ug 2-iminoethyl-1-thioglycoside of
galactose per mg derivative (about one-third of the 
lysine residues were substituted). Ara-AMP was 
coupled to poly(L-lysine) or to Gal-poly(L-lysine) 
using 1-ethyl-3-(dimethylaminopropyl)carbodi- 
imide (ECDI). 290 mg ara-AMP and 80 mg 
polymer were dissolved in 1.2 ml Hz0 and the pH 
was adjusted to 7.5 with 10 N NaOH. After the ad- 
dition of 290 mg ECDI the mixture was incubated 
for 24 h at 45°C and then dialyzed against 0.9% 
NaCl. Precipitated material was removed by cen- 
trifugation and the weight ratio (w/w) ara- 
AMP/poly(L-lysine) was determined by calculat- 
ing the ara-AMP concentration from the extinc- 
tion at 260 nm (El% = 420) and measuring the 
polymer according to Gornall et al. [lo]. The ratios 
were 0.60 and 0.18 for poly(L-lysine)-ara-AMP, 
and Gal-poly(L-lysine)-ara-AMP, respectively. 
Conjugation with ACV was performed by con- 
verting the drug into its monophosphate form 
(ACV-MP). ACV was phosphorylated by adding 
phosphorus oxychloride to a cold ( - 2°C) suspen- 
sion of the drug in triethylphosphate (11,121. 
ACV-MP was purified by chromatography on a 
Dowex-1-formate column eluted with a formic 
acid gradient (O-4 M). It was found to be essen- 
tially pure with a ratio of base (El” = 529 at 
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255 nm in 0.1 M HCI) to phosphate [13] of 1: 1. of “C-labelled asialofetuin from the blood of 
Thin-layer chromatography performed on pre- mice. Fetuin is a glycoprotein which, following 
coated silica gel plates (60 F-254; Merck) with n- desialylation and consequent exposure of galac- 
propanol-concentrated ammonium hydroxide- tosyl residues, is removed from the blood selective- 
water (20: 20: 3, v/v) showed only one spot with a ly by the liver after being bound by this receptor 
Rf of 0.51. ACV-MP was coupled to Gal-poly(L- [2]. For reasons unknown, Gal-poly(L-lysine) 
lysine) with the same procedure used for ara-AMP. when conjugated with ara-AMP or ACV-MP in- 
The weight ratio (w/w) ACV-MP/Gal-poly(L- hibited AF clearance to a significantly higher ex- 
lysine) was 0.11. tent than the nucleotide-free polymer. 
Coupling of D-galactosyl residues to human 
serum albumin (HSA) was obtained by reductive 
lactosamination of lysine residues [14]. The molar 
ratio lactose/HSA was 30; ara-AMP and ACV- 
MP were coupled to lactosaminated HSA (L-HSA) 
as previously described [6]; the molar ratios of 
drug/carrier were 13 and 10, respectively. 
3. RESULTS AND DISCUSSION 
Gal-poly(L-lysine) interacted with the hepatic 
receptor for galactosyl terminating glycoproteins. 
As shown in table 1, it inhibited the disappearance 
Table 1 
Effect of poly(L-lysine), Gal-poly(L-lysine) and 
conjugates of Gal-poly(L-lysine) with ara-AMP or 
ACV-MP on plasma disappearance of [‘4C]asialofetuin 
(AF) 
Compound injected with [14C]AF 
None 5506 f 752 
Poly(L-lysine) 5308 + 300 
Gal-poly(L-lysine) 13268 f 145 
Gal-poly(L-lysine)-ara-AMP 20056 + 642 
Gal-poly(L-lysine)-ACV-MP 16732 & 342 
Fetuin was enzymatically desialylated and labelled with 
[‘4C]formaldehyde as described [4]. Swiss female mice 
(28-30 g) were injected i.v. with 2 pg/g body wt [14C]AF 
(4.9 x lo6 dpm/mg). The compounds were administered 
i.v. simultaneously with [14C]AF at 2pg/g. In all cases 
the volume injected was 10 PI/g. After 10 min mice were 
bled from retroorbital plexus under ether anaesthesia 
and the radioactivity of plasma was measured. Each 
entry (dpm/200 pl) represents the mean value f SE of 
results from 7 animals. The difference between the 
results from mice injected with Gal-poly(L-lysine) or 
with the drug conjugates was statistically significant as 
Table 2 shows the effect of free and coupled 
drugs on [methyl-3H]thymidine incorporation into 
DNA in liver, intestine and bone marrow of mice 
with Ectromelia virus hepatitis. In these animals 
thymidine incorporation in liver is almost certainly 
due to virus DNA synthesis [4]. Free ara-AMP in- 
jected at the dose of 7.5 pg/g, which corresponds 
to that administered to patiens with chronic 
hepatitis B [7], inhibited DNA synthesis in the 
three organs. Poly(L-lysine)-ara-AMP produced 
significant inhibition in liver and intestine; Gal- 
poly(L-lysine)-ara-AMP and L-HSA-ara-AMP in- 
hibited DNA synthesis only in liver. The results 
with free ara-AMP and with L-HSA-ara-AMP 
confirmed previous data [4-61. ACV and ACV- 
MP were not active at the dose of 5 pg/g body wt. 
ACV significantly inhibited DNA synthesis in liver 
and intestine at the dose of lOpg/g which cor- 
responds to that used in patients with chronic 
hepatitis B [7]. ACV-MP coupled to Gal-poly(L- 
lysine), tested at 1 .l and 2.2 ,ug ACV/g, was inef- 
fective in the three organs; higher amounts of this 
complex could not be injected because of its toxici- 
ty (see below). ACV-MP conjugated with L-HSA 
inhibited DNA synthesis in liver at the dose of only 
0.6 pg/g without producing significant inhibition 
in intestine and bone marrow. In conclusion Gal- 
poly(L-lysine) accomplished a liver targeting of 
ara-AMP but not of ACV-MP. The reason why 
ACV-MP was active only when coupled to L-HSA 
may depend on the different bonds between the 
drug and the two carriers. In the conjugate with 
Gal-poly(L-lysine) the drug is linked by a 
phosphoamide bond, while its bond(s) with L- 
HSA have not been identified as yet. 
evaluated by Student’s t-test 
Gal-poly(L-lysine) possesses some advantages 
over L-HSA as a hepatotropic carrier of ara-AMP: 
(i) it is obtained by a synthetic method; (ii) it is 
available in a wide range of molecular sizes; (iii) it 
contains a large number of functional groups to 
which the drug can be coupled. On the other hand, 
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Table 2 
Effect of free and coupled ara-AMP and ACV on [methyl-3H]thymidine incorporation i to DNA of liver, intestine and 
bone marrow of Ectromelia virus-infected mice 
Compound Dose Ara-AMP or ACV Inhibition of [methyl-‘Hlthymidine 
@g/g) administered incorporation (Ore) 
@g/g) 
Liver Intestine Bone marrow 
Ara-AMP 7.5 7.5 49(S)a 61(S) 34(S) 
Poly(L-lysine)-ara-AMP 8 3.0 55(S) 40(S) 16fNS)’ 
12 4.5 57(S) 50(S) 1 l(NS) 
Gal-poly(L-lysine)-ara-AMP 10 1.5 29(S) 0 0 
20 3.0 51(S) 2 0 
2ob 3.0 25(S) 0 
L-HSA-~a-AMP 50 3.2 fO(S) 6(NS) :NS) 
ACV 5 5 0 7 
10 10 42(S) 38(S) l:(NS) 
100 100 65(S) 75(S) 59(S) 
ACV-MP 6.8 5 15(NS) 23(NS) 
Gal-poly(L-lysine)-ACV-MP 
20(NS) 
10 1.i 0 3 5 
20 2.2 1 l(NS) 1 I(NS) 
L-HSA-ACV-MP 
13(NS) 
25 0.6 40(S) 6(NS) 0 
50 1.2 55(S) 16(NS) 7@JS) 
a Results were statistically evaluated by means of Student’s t-test. The difference was considered statistically significant 
(S) or not significant (NS) for PC or >O.OS, respectively 
b In this experiment he conjugate was injected 2 h before [methyl-‘Hlthymidine 
Experiments were performed as described (51; when free or coupled ACV was administered, the injection of 9-erythro- 
(2-hydroxyl-3-nonyl)adenine was omitted. Compounds were injected 1 h before [methyl-3H]thymidine. In control 
animals the mean values of dpm/l~~g DNA ranged in the different ex~riments from 14177 to 24692 in liver, from 
19141 to 24121 in intestine and from 16967 to 21289 in bone marrow 
L-HSA and its conjugates with ara-AMP do not 
display any recognizable sign of toxicity even at 
high doses [6] whereas poly(L-lysine) is rather toxic 
[8,15]. Glycosylation reduces this toxicity; in fact 
we found that the LDSO of the poly(L-lysine) used 
in these experiments increased from 20 to 40 pg/g 
body wt after coupling to galactosyl residues. Fur- 
ther experiments will be undertaken to elucidate 
whether by substituting a higher number of c-NH2 
groups, the toxicity of Gal-poly(L-lysine) can be 
decreased to levels compatible with clinical use. 
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